PARIS – Stilla Technologies SAS, of Villejuif, France, is supplying a new, cost-effective approach for COVID-19 testing by combining its digital polymerase chain reaction (PCR) technology with the group testing method. “This approach greatly increases testing capacity and meets the highest quality standards,” Rémi Dangla, co-founder and CEO of Stilla Technologies, told BioWorld.
COLOMBIA – The COVID-19 pandemic has put Latin America’s biotech sector under extreme pressure and highlighted flaws in the ecosystem throughout the region, not the least of which is a lack of viable networks to facilitate cooperation.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Anpac Bio, Beijing Yuan Jian Health Management, Koru Medical Systems, Masimo, Pixium, Seizure Tracker, Tuberous Sclerosis Alliance.
PERTH, Australia – Australia’s largest life science investment fund is pressing the government for an urgent COVID-19 response package to support the country’s AU$170 billion (US$117 billion) life sciences sector that is struggling to survive in a post-COVID-19 ecosystem.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acasti, Ampio, Ascentage, Beigene, Innovent, Nymox, Ovid, Plakous, Redhill, Regeneron, Sanofi.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Acerus, Achilles Vaccines, Adamis, Assembly, Hemostemix, Immuron, Kane Biotech, Merck, Oncolys, Oryzon, Themis, Tiziana.
Beverly, Mass.-based Lexagene Holdings Inc. has developed a genetic analyzer with multiplex testing capability that would enable it to determine whether a patient has COVID-19, influenza or another respiratory infection with one sample. The Lx Analyzer uses a proprietary quantitative reverse transcription polymerase chain reaction (RT-qPCR) method to automatically test for up to 27 pathogens simultaneously, all in about one hour.
The potential for neurological complications, including seizures and stroke, is a growing concern with COVID-19 patients. To ensure rapid diagnosis and treatment, Ceribell Inc., a Mountain View, Calif.-based startup, is deploying its cloud-linked, portable electroencephalogram (EEG) device to enable EEG assessments in minutes in emergency rooms and intensive care units.
RSS
